Investor Meeting and Presentation

RNS Number : 4810B

Avacta Group PLC

21 September 2018

 

                                                                                                                           21 September 2018                         

Avacta Group plc

("Avacta", the "Group" or the "Company")

Investor Meeting and Presentation

Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that Alastair Smith, CEO of Avacta, will be presenting at an investor evening hosted by Turner Pope Investments (TPI) Ltd. TPI acted as a joint agent in the recent £11.6m placing by Avacta Group plc.

The event will be held on 1^st October, London, EC2 and will commence at 5.00pm. To Register your interest, please email [e-mail] or call 0203 621 4121.

- Ends -

For further information from Avacta Group plc, please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer	Tel:  [phone] www.avacta.com
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Nikita Jain - Corporate Broking WG Partners Nigel Birks / Nigel Barnes David Wilson / Claes Spang	Tel:  [phone] www.finncap.com Tel:  [phone] Tel:  [phone] www.wgpartners.co.uk
Turner Pope James Pope Andy Thacker	Tel:  [phone] www.turnerpope.com
Zyme Communications (Trade and Regional Media) Katie Odgaard Yellow Jersey (Financial Media and IR) Sarah Hollins	Tel: [phone] [e-mail]  Tel: [phone] [e-mail]

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer^® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability.  Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

 

END

 

 

NRAEAANEADPPEAF